Display options
Cite
Marini A, Bernardini A, Gigli GL, et al. Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Neurology. 2021;96(16):754-766doi: 10.1212/WNL.0000000000011795.
Marini, A., Bernardini, A., Gigli, G. L., Valente, M., Muñiz-Castrillo, S., Honnorat, J., & Vogrig, A. (2021). Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Neurology, 96(16), 754-766. https://doi.org/10.1212/WNL.0000000000011795
Marini, Alessandro, et al. "Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review." Neurology vol. 96,16 (2021): 754-766. doi: https://doi.org/10.1212/WNL.0000000000011795
Marini A, Bernardini A, Gigli GL, Valente M, Muñiz-Castrillo S, Honnorat J, Vogrig A. Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Neurology. 2021 Apr 20;96(16):754-766. doi: 10.1212/WNL.0000000000011795. Epub 2021 Mar 02. PMID: 33653902.
Copy Download .nbib Format: NLM
Share it on

Neurology. 2021 Apr 20;96(16):754-766. doi: 10.1212/WNL.0000000000011795. Epub 2021 Mar 02.

Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review.

Neurology

Alessandro Marini, Andrea Bernardini, Gian Luigi Gigli, Mariarosaria Valente, Sergio Muñiz-Castrillo, Jérôme Honnorat, Alberto Vogrig

Affiliations

  1. From the Clinical Neurology Unit (A.M., A.B., G.L.G., M.V., A.V.), Santa Maria Della Misericordia University Hospital; Department of Medicine (DAME) (A.M., G.L.G., M.V.), University of Udine Medical School, Italy; French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (S.M.-C., J.H., A.V.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team (S.M.-C., J.H., A.V.), NeuroMyoGene Institute, INSERM U1217/CNRS UMR5310; and University Claude Bernard Lyon 1 (S.M.-C., J.H., A.V.), Université de Lyon, France.
  2. From the Clinical Neurology Unit (A.M., A.B., G.L.G., M.V., A.V.), Santa Maria Della Misericordia University Hospital; Department of Medicine (DAME) (A.M., G.L.G., M.V.), University of Udine Medical School, Italy; French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (S.M.-C., J.H., A.V.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team (S.M.-C., J.H., A.V.), NeuroMyoGene Institute, INSERM U1217/CNRS UMR5310; and University Claude Bernard Lyon 1 (S.M.-C., J.H., A.V.), Université de Lyon, France. [email protected].

PMID: 33653902 DOI: 10.1212/WNL.0000000000011795

Abstract

OBJECTIVE: To define the clinical characteristics, management, and outcome of neurologic immune-related adverse events (n-irAEs) of immune checkpoint inhibitors (ICIs).

METHODS: Systematic review of the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

RESULTS: A total of 694 articles were identified. Two hundred fifty-six articles, with 428 individual patients, met the inclusion criteria. Reports regarding neuromuscular disorders (319/428, 75%) were more frequent than those on CNS disorders (109/428, 25%). The most common n-irAEs reports were myositis (136/428, 32%), Guillain-Barré syndrome and other peripheral neuropathies (94/428, 22%), myasthenic syndromes (58/428, 14%), encephalitis (56/428, 13%), cranial neuropathies (31/428, 7%), meningitis (13/428, 3%), CNS demyelinating diseases (8/428, 2%), and myelitis (7/428, 2%). Other CNS disorders were detected in 25/428 (6%) patients. Compared with the whole sample, myasthenic syndromes were significantly more Ab positive (33/56, 59%;

CONCLUSION: Considering the increasing use of ICI therapy in the forthcoming future, this information can be valuable in assisting neurologists and oncologists in early n-irAEs diagnosis and treatment.

© 2021 American Academy of Neurology.

Substances

MeSH terms

Publication Types